Thursday 16 October, 2025
Objectives: The protease inhibitor (PI) saquinavir (SQV) is characterized by a low and variable oral bioavailiability [1], which can be…
Read morePoster: Applications- Anti-infectives
Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions
Thursday 16 October, 2025
Background: Fluconazole is a potent antifungal agent used for both prophylactic and systemic treatment of candidiasis. However, we do not…
Read moreInfluence of pharmacogenetic on pharmacokinetic interindividual variability of indinavir and lopinavir in HIV patients (COPHAR2 – ANRS 111 trial)
Thursday 16 October, 2025
Objectives: To evaluate the effect of genetic polymorphisms on indinavir and on lopinavir pharmacokinetic (PK) variability in HIV-infected patients initiating…
Read moreNew Insights into the Most Commonly Studied Drug Interaction with Antibiotics: Pharmacokinetic Interaction between Ciprofloxacin, Gemifloxacin and Probenecid at Renal and Non-renal Sites
Thursday 16 October, 2025
PDF of posterObjectives: Probenecid interacts with transport processes of drugs at several sites in the body. We modeled gemifloxacin in…
Read moreBias and Uncertainty of Monte Carlo Simulations with Beta-Lactams
Thursday 16 October, 2025
PDF of poster Objectives: The majority of published papers on Monte Carlo simulations (MCS) with beta-lactams use pharmacokinetic (PK) parameters…
Read moreMechanism-based Modelling of the Synergy of Colistin Combinations against Multidrug-Resistant Gram Negative Bacteria
Thursday 16 October, 2025
Objectives: Design of rational antibiotic combination regimens is critical to treat infections by multidrug-resistant (MDR) A. baumannii (Ab), K. pneumoniae…
Read moreTobramycin in paediatric CF patients – TCI or “One dose fits all”
Thursday 16 October, 2025
Objectives: The aim of this study was to i) develop a population pharmacokinetic model for tobramycin in paediatric cystic fibrosis…
Read morePaediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients
Thursday 16 October, 2025
PDF of poster Objectives: The aim of the study was to characterise the population pharmacokinetics (popPK) properties of itraconazole (ITRA)…
Read morePopulation pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus
Thursday 16 October, 2025
Objectives: Cytomegalovirus (CMV) is a leading cause of disease in immunocompromised subjects, such as solid organ transplant recipients. Valganciclovir (VGC), an…
Read morePopulation pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus
Thursday 16 October, 2025
PDF of poster Introduction and Objectives: Cytomegalovirus (CMV) is a leading cause of disease in immunocompromised subjects, as solid organ…
Read more